Innate Pharma Starts Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

 

• Partner Sanofi advances SAR’514 / IPH6401, a trifunctional anti-BCMA NKp46xCD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, to first-in-human clinical trial in relapsed/refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
• Second molecule from Innate’s multi-specific NK cell engager platform ANKET^® to progress to the clinic

https://www.biospace.com/article/releases/first-patient-dosed-in-sar-514-iph6401-phase-1-2-clinical-trial-in-relapsed-refractory-multiple-myeloma/